SlidesetHIVSecond generation INSTI regimens for drug naive patients: State of the Art - Daniel Kuritzkes, MDView Slideset
SlidesetHIVFirst line regimens in different European countries 2019 – an overview - Miłosz Parczewski, MD, PhDView Slideset
SlidesetHIVWhen to start antiretroviral therapy after diagnosis – trade-offs and considerations - Anton Pozniak, MD, FRCPView Slideset
SlidesetHIVSingle-Tablet Regimens Versus Multiple Pills: Is There a Meaningful Difference? - Bonaventura Clotet, MD, PhDView Slideset
SlidesetHIVImpact on transmitted and acquired drug resistance - Anne-Geneviève Marcelin, PharmD, PhDView Slideset
SlidesetHIVLong-Acting Parenteral Antiretroviral Regimens: Where Might They Fit? - Saye Khoo, MD, PhDView Slideset
SlidesetHIVImpact on children and adolescence - Natella Rakhmanina, MD, PhD, FAAP, FCP, AAHIVSView Slideset